Stock-research Ratings: HighPoint Resources Corporation (HPR), EyePoint Pharmaceuticals, Inc. (EYPT)

HighPoint Resources Corporation (NYSE:HPR) tinted gains of +4.47% (+0.11 points) to US$2.57. The volume of 1.28 Million shares climbed down over an trading activity of 1.81 Million shares. EPS ratio determined by looking at last 12 month figures is -1.5. Over the same time span, the stock marked US$7.6 as its best level and the lowest price reached was US$2.06. The corporation has a market cap of US$549.54 Million.

HighPoint Resources Corporation (NYSE:HPR)’s earnings per share has been growing at a -70.38 percent rate over the past 5 year when average revenue increase was noted as -18.4 percent. The return on equity ratio or ROE stands at -19.6 percent while most common profitability ratio return on investment (ROI) was -6 percent. The company’s institutional ownership is monitored at 97 percent. The company’s net profit margin has achieved the current level of -44.1 percent and possesses 84.3 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 2.17. 7 analysts recommended Overweight these shares while 1 recommended Underweight, according to FactSet data.

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is worth US$238.85 Million and has recently risen 4.25% to US$2.7. The latest exchange of 0.46 Million shares is below its average trading activity of 393.28 Million shares. The day began at US$2.67 but the price moved to US$2.66 at one point during the trading and finally capitulating to a session high of US$2.67. The stock tapped a 52-week high of US$3.94 while the mean 12-month price target for the shares is US$6.17.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 4.11, and a price to sales ratio of 77.05. For the past 5 years, the company’s revenue has grown 6.7%, while the company’s earnings per share has grown -17.4%. With an institutional ownership near 57%, it carries an earnings per share ratio of -1.35.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.